Covered Call On Medical Devices ETFs Innovation Cycle Exposure

David V. has been in my program a little over a year now. He’s up roughly 47%, always trades in-the-money covered calls, and plays a lot of golf. Boring system. Boring makes you rich. Exciting doesn’t make you rich.

What I like about David is that he stuck to the plan even when the market got noisy. When everyone else was chasing AI names in 2023 and 2024, he kept running his covered calls on the same steady names: healthcare REITs, utilities, and a basket of medical devices ETFs he barely talked about. He didn’t need to talk about them. They were working.

That’s the thing about medical devices. The innovation cycles are real, the demographic tailwinds are unstoppable, and the revenue visibility is better than most sectors give you. But you don’t need to pick the next breakthrough pacemaker or robotic surgery platform. You can own the whole field through ETFs and get paid while you wait. Here’s how I think about covered calls on medical devices ETFs and why they deserve a place in your income portfolio.

The Case for Medical Devices in a Covered Call Strategy

I’ve been through enough cycles to know that some sectors are built for income investing and others are built for speculation. Medical devices sits in a sweet spot between the two.

On the one hand, you have genuine innovation. FDA approvals, new product launches, M&A activity, global expansion into emerging markets. These are real growth drivers. On the other hand, you have something most tech companies would kill for: recurring revenue from installed bases, procedure volumes that track with demographics, and pricing power that comes from regulatory moats.

The covered call strategy works best on assets that don’t gap 30% overnight on a tweet. Medical devices ETFs give you that stability. The iShares U.S. Medical Devices ETF (IHI), the SPDR S&P Health Care Equipment ETF (XHE), and the First Trust Indxx Medical Devices ETF (MDYV) all hold diversified baskets of established players. Abbott, Medtronic, Intuitive Surgical, Stryker. These are companies with decades of cash flow history, not pre-revenue biotech lottery tickets.

What this means for your covered call writing: you can sell closer-to-the-money strikes with more confidence. The implied volatility is elevated enough to generate meaningful premium (typically 15-25% higher than broad market ETFs), but the realized volatility is more contained. You collect more. You stress less.

Mapping the Innovation Cycle to Your Call Strategy

The medical devices sector runs on predictable rhythms. Understanding them lets you time your covered call strikes more intelligently.

First, the FDA calendar. Panel meetings for breakthrough devices, PMA approvals for high-risk categories, 510(k) clearances for incremental innovations. These create volatility windows. When a major player in your ETF has a panel date approaching, implied volatility expands. That’s your opportunity to sell calls at richer premiums.

Second, earnings clustering. Medical devices companies tend to report in clusters: late January, late April, late July, late October. The two weeks before these clusters is prime time for call writing. You’re capturing elevated time decay and volatility premium.

Third, the major conferences: the Transcatheter Cardiovascular Therapeutics (TCT) meeting in late fall, the American College of Cardiology (ACC) in spring, the Radiological Society of North America (RSNA) in late November. These are where companies unveil data and set guidance. The run-up creates option premium. The aftermath often creates consolidation where you want to own the underlying.

My approach: during the 2-3 weeks before these catalysts, I sell shorter-dated calls (2-4 weeks out) at strikes 2-5% out-of-the-money. I’m capturing the volatility expansion without committing to a long-dated structure that might get blown through by a surprise approval. After the catalyst passes and volatility collapses, I either let the calls expire worthless and rewrite, or I roll down to capture more premium if the stock has drifted lower.

The ETFs Worth Your Attention

Not all medical devices ETFs are created equal for covered call purposes. I focus on three, each with different characteristics.

IHI (iShares U.S. Medical Devices) is the liquid giant. $6 billion in assets, tight bid-ask spreads, options markets that are deep and responsive. Holdings skew toward large-cap: Abbott, Thermo Fisher, Danaher, Medtronic. The top 10 names are 60%+ of the fund. This concentration is actually helpful for covered calls. You’re not diluting your premium across 100 tiny positions. The options trade cleanly, and you can get fills on spreads without bleeding edge on execution.

XHE (SPDR S&P Health Care Equipment) is more evenly weighted. No single name is more than 4-5% of the fund. This gives you more diversification but slightly lower implied volatility on the ETF itself. I use XHE when I want medical devices exposure but I’m worried about single-stock risk in IHI’s heavyweights. The options are less liquid, so I stick to monthly expirations and avoid the weeklies.

MDYV (First Trust Indxx Medical Devices) is the international play. Roughly 40% ex-U.S. exposure, including Japanese and European device makers. This gives you currency diversification and access to markets with different approval timelines. The options market is thinner, so this is for larger position sizes where you can get institutional-sized fills. I use MDYV sparingly, but it’s valuable when the dollar is weakening and you want that tailwind.

One more to watch: SBIO (ALPS Medical Breakthroughs) is more speculative, weighted toward clinical-stage companies. Higher volatility, bigger premiums, but also bigger gap risk. I don’t run covered calls here. The distribution of returns has too much left-tail risk. Stick to the established players.

Position Sizing and Portfolio Construction

Here’s a rule I learned the hard way in 2008, then relearned in 2020: no single sector should dominate your covered call book. Medical devices is attractive, but it’s still healthcare, still sensitive to regulatory risk, still vulnerable to procedure volume shocks (see: COVID-19 elective surgery cancellations).

I cap medical devices ETFs at 15-25% of my total covered call allocation. Within that bucket, I split between IHI (60%), XHE (30%), and MDYV (10%). This gives me liquidity where I need it, diversification where I want it, and international exposure as a hedge.

The rest of my covered call portfolio runs across utilities, REITs, gold miners, and select tech names with defensive characteristics. The goal is income streams that don’t all correlate. When one sector’s volatility collapses and premiums dry up, another is usually expanding.

For position sizing within the medical devices allocation, I use a simple rule: no single ETF position should generate more than 10% of my monthly covered call income. This forces diversification and prevents overconfidence in any one name. I’ve seen too many traders fall in love with a “can’t miss” sector and get punished when the cycle turns.

When to Adjust Your Approach

The medical devices innovation cycle isn’t static. Three conditions should prompt you to tighten your covered call strikes or reduce exposure entirely.

First, when the FDA announces major regulatory shifts. The shift to premarket approval for certain software-as-a-medical-device products in 2022-2023 created uncertainty that took months to resolve. During those windows, I moved my strikes further out-of-the-money and shortened my durations. I wanted to capture premium without committing to structures that might get tested by a sector-wide repricing.

Second, when reimbursement headlines turn negative. CMS decisions on device coverage can move stocks faster than FDA actions. The 2023 debates over continuous glucose monitor coverage created volatility spikes in Abbott and Dexcom that rippled through IHI. I reduced my IHI position by 30% during that window and added to XHE’s more diversified structure.

Third, when valuation multiples stretch beyond historical norms. Medical devices has traded at a premium to the broad market for decades, but there are limits. When forward P/Es on IHI’s top holdings exceed 25x and the dividend yield on the ETF drops below 0.5%, I get more conservative with my strike selection. The upside capture matters more when you’re paying up for the underlying.

What is the best medical devices ETF for covered calls?

IHI offers the best combination of liquidity, options depth, and premium generation for most covered call writers. Its concentrated large-cap holdings produce meaningful implied volatility without the gap risk of smaller names. XHE works for those wanting more diversification, while MDYV adds international exposure for larger accounts.

How do FDA approval cycles affect covered call premiums on medical devices ETFs?

FDA panel meetings and approval decisions create predictable volatility windows. Implied volatility typically expands 15-30% in the two weeks before major catalysts, letting you sell richer premiums. After the event, volatility collapses rapidly. Structure shorter-dated calls before catalysts to capture this expansion without long-dated commitment.

Should I use weekly or monthly options for medical devices ETF covered calls?

Monthly options on IHI offer the best balance of premium capture and execution quality. Weeklies exist but spreads are wider and liquidity is patchy. For XHE and MDYV, stick to monthlies exclusively. The extra premium from weeklies isn’t worth the execution risk in thinner markets.

Medical devices ETFs won’t make you rich overnight. They’re not the Tesla trade of 2020. What they offer is something better for the covered call writer: predictable volatility, demographic tailwinds you can ride for decades, and premium generation that compounds quietly while you focus on other things. David V. figured this out. His golf game is improving, and his account keeps growing. Boring wins.

If you want to see exactly how I structure these trades, start with a free trial of Cash Flow IQ. You’ll get my current watchlist, strike selection framework, and the circuit breaker rules that keep losses contained when cycles turn. Plus access to our community of traders who’ve been through enough markets to know that slow and steady isn’t just a cliché. It’s the whole game.

This is education, not financial advice. Past performance is not indicative of future results. Consult a qualified advisor before making investment decisions.